Chest Mobility, Strength, Physical Activity and Quality of Life in Parkinson's Patients With Post-COVID-19

Chest Mobility, Cough Strength, Muscle Strength, Physical Activity and Quality of Life in Parkinson's Patients Who Have Had COVID-19

To comparative pain intensity, chest mobility, cough strength, muscle strength, physical activity levels and quality of life in Parkinson's patients with post-COVID-19 and without post-COVID-19 was aimed in current study. Knowledge in the literature regarding this topic is still obscure.

Acute worsening and long-term sequelae of motor and non-motor symptoms have also been described in Parkinson's patients during and after SARS-CoV-2 infection, which is also known as prolonged COVID. The effects of COVID-19 on pain, chest mobility, cough strength, muscle strength, physical activity levels and quality of life in Parkinson's patients are still unclear today. For this reason, in this study, it was aimed to comparatively investigate pain, chest mobility, cough strength, muscle strength, physical activity levels and quality of life in Parkinson's patients with COVID-19 and without COVID-19 and to show the relationships between these outcome measures.

Inclusion Criteria for Parkinson's patients with post-COVID-19;

• Being diagnosed with COVID-19 at least 12 weeks ago and recovered,
• Being over 18 years old,
• Volunteering to participate in the research,
• Being diagnosed with Parkinson's disease
• Comorbid conditions (such as hypertension, diabetes) are under control
• Being able to perceive assessments (Standardized Mini Mental Test score of 24 and above)
• Having the ability to ambulate and walk independently
• Being in stage 1 - 4 according to the Modified Hoehn-Yahr Scale

Inclusion criteria for Parkinson's patients without post-COVID-19;

• Not being diagnosed or suspected of COVID-19
• Being over 18 years old,
• Volunteering to participate in the research,
• Being diagnosed with Parkinson's disease
• Having comorbid conditions (such as hypertension, diabetes) which are under control
• Being able to perceive assessments (Standardized Mini Mental Test score of 24 and above)
• Having the ability to ambulate and walk independently
• Being in stage 1 - 4 according to the Modified Hoehn-Yahr Scale

Exclusion criteria for Parkinson's patients with and without post-COVID-19;

• Sudden drug or dose change during the study period
• A history of any acute/chronic orthopedic, cardiovascular, pulmonary, psychiatric or neuromuscular disease that may prevent measurements from being made.
• Having had myocardial infarction and pulmonary embolism in the last 30 days,
• Having a history of additional neurological (stroke, head trauma, peripheral nerve diseases, brain and spinal cord tumors, etc.) diseases other than Parkinson's disease
• Having severe vision loss or vestibular dysfunction
• Patients with blood pressure values above 140/90 and below 90/50 in blood pressure measurements made before the study, with arrhythmia on ECG, with a history of shortness of breath and/or palpitation